Get the Stockscreener App
10.84
1.31%
0.14
After Hours:
10.74
-0.10
-0.92%
Benitec Biopharma Inc stock is traded at $10.84, with a volume of 94,515.
It is up +1.31% in the last 24 hours and down -1.45% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$10.70
Open:
$10.87
24h Volume:
94,515
Relative Volume:
0.56
Market Cap:
$371.32M
Revenue:
$7,000
Net Income/Loss:
$-38.96M
P/E Ratio:
-11.66
EPS:
-0.9296
Net Cash Flow:
$-18.34M
1W Performance:
-7.19%
1M Performance:
-1.45%
6M Performance:
-21.45%
1Y Performance:
-26.11%
1-Day Range:
$10.66
$11.13
1-Week Range:
$10.50
$11.85
52-Week Range:
$9.85
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
10.84 | 366.53M | 7,000 | -38.96M | -18.34M | -0.9296 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Below Fifty Day Moving Average – Here’s What Happened - Defense World
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
(BNTC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Market Moves: Is Benitec Biopharma Inc forming a double bottom2026 Closing Moves & Verified Short-Term Plans - baoquankhu1.vn
BNTC SEC FilingsBenitec Biopharm 10-K, 10-Q, 8-K Forms - Stock Titan
Benitec Biopharma (NASDAQ: BNTC) FY 2025 loss widens to $37.9M - Stock Titan
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Risk Recap: What is the dividend yield of Benitec Biopharma Inc2026 Setups & Low Drawdown Trading Strategies - baoquankhu1.vn
Portfolio Recap: Is Benitec Biopharma Inc stock a good dividend stockDollar Strength & High Accuracy Swing Trade Signals - baoquankhu1.vn
Jerel A. Banks, MD, PhD, on Evaluating Gene Therapy BB-301 for OPMD-Related Dysphagia - CGTLive®
Surprises Report: Can Benitec Biopharma Inc maintain its current growth rate2026 Fundamental Recap & Intraday High Probability Alerts - baoquankhu1.vn
(BNTC) Risk Channels and Responsive Allocation - Stock Traders Daily
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for - The Manila Times
Benitec Biopharma to Host Industry Forum Breakfast Event at - GlobeNewswire
Benitec Biopharma (NASDAQ:BNTC) Receives Buy Rating from HC Wainwright - Defense World
Breakfast talk to show OPMD swallowing gains from gene therapy BB-301 - Stock Titan
Benitec Biopharma Inc. (BNTC) Competitors - Meyka
Cowen Reiterates Buy on Benitec Biopharma (BNTC) March 2026 - Meyka
Benitec Biopharma : Corporate Presentation, March 2026 - marketscreener.com
Benitec BioPharma stock maintains Buy rating on positive trial data By Investing.com - Investing.com South Africa
Benitec BioPharma stock maintains Buy rating on positive trial data - Investing.com
BNTC: HC Wainwright & Co. Reiterates Buy Rating on Benitec Bioph - GuruFocus
Benitec reports interim results from gene therapy trial - Investing.com Nigeria
Benitec Biopharma (BNTC) Reports Encouraging Interim Results fro - GuruFocus
Benitec Biopharma Announces Positive Interim Phase 1b/2a - GlobeNewswire
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Bitget
Benitec Biopharma Stock Pre-Market (+7.1%): Analyst Raises EPS Forecasts - Trefis
Sentiment Recap: What is the Moat Score of Benitec Biopharma IncJuly 2025 Outlook & Stock Timing and Entry Methods - baoquankhu1.vn
New Highs: How liquid is Benitec Biopharma Inc stockJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
HC Wainwright Expects Higher Earnings for Benitec Biopharma - Defense World
HC Wainwright Issues Optimistic Forecast for BNTC Earnings - MarketBeat
Levels Update: Is Benitec Biopharma Inc exposed to political riskTreasury Yields & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Research Analysts Offer Predictions for BNTC Q1 Earnings - Defense World
Analysts Issue Forecasts for BNTC Q1 Earnings - MarketBeat
(BNTC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Benitec Biopharma Inc. (BNTC) - DirectorsTalk Interviews
Benitec BioPharma stock rating maintained on gene therapy data - Investing.com Nigeria
Benitec BioPharma stock rating maintained on gene therapy data By Investing.com - Investing.com Australia
Benitec Biopharma Announces Acceptance of Late- Breaking - GlobeNewswire
Durable BB-301 responses in muscular dystrophy to be detailed at MDA 2026 - Stock Titan
Benitec Biopharma (BNTC) Stock Analysis: Unpacking A 125% Potential Upside - DirectorsTalk Interviews
Liquidity Mapping Around (BNTC) Price Events - Stock Traders Daily
What insider trading reveals about Benitec Biopharma Inc. stockJuly 2025 Opening Moves & Verified Swing Trading Watchlists - mfd.ru
Growth Value: What insider trading reveals about Benitec Biopharma Inc. stockMarket Trend Summary & Smart Money Movement Alerts - mfd.ru
Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation - Yahoo Finance
Hedge funds owners may consider drastic measures as Benitec Biopharma Inc.'s (NASDAQ:BNTC) recent US$60m drop adds to long-term losses - simplywall.st
Wall Street Zen Downgrades Benitec Biopharma (NASDAQ:BNTC) to Sell - MarketBeat
BNTC PE Ratio & Valuation, Is BNTC Overvalued - Intellectia AI
Benitec Biopharma (NASDAQ:BNTC) Announces Quarterly Earnings Results - MarketBeat
Benitec Biopharma Inc. (BNTC) Investor Outlook: Analyst Ratings Signal a Promising 104.58% Upside Potential - DirectorsTalk Interviews
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):